Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus

References

• Kamal A, Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev. 2014;13:1094–1101. DOI:10.1016/j.autrev.2014.08.020.
   Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–939. DOI:10.1056/NEJMra071297.
   Google Scholar
• Chan VS-F, Tsang HH-L, Tam RC-Y, et al. B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol. 2013;10:133–142. DOI:10.1038/cmi.2012.64.
   Google Scholar
• Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001;2:764–766. DOI:10.1038/ni0901-764.
   Google Scholar
• Arvieux J, Renaudineau Y, Mane I, et al. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost. 2002;87:599–605.
   Google Scholar
• Swaak T, Smeenk R. Clinical significance of antibodies to double stranded DNA (dsDNA) for systemic lupus erythematosus (SLE). Clin Rheumatol. 1987;6(Suppl 1):56–73.
   Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533. DOI:10.1056/NEJMoa021933.
   Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215–1226. DOI:10.1002/art.34359.
   Google Scholar
• Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol. [cited 2015 Dec 14]. 2015;33:449–456. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26053285
   Google Scholar
• Al Rayes H, Touma Z. Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2014;8:2303–2310. DOI:10.2147/DDDT.S49778.
   Google Scholar
• Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402. DOI:10.1182/blood-2009-06-225979.
   Google Scholar
• Schindler T, Rovin B, Furie R, et al. NOBILITY, a phase 2 trial to assess the safety and efficacy of obinutuzumab, a novel type 2 anti-cd20 monoclonal antibody (mab), in patients (pts) with isn/rps class iii or iv lupus nephritis (LN). Ann Rheum Dis. 2016;75:1051. DOI:10.1136/annrheumdis-2016-eular.2397.
   Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930. DOI:10.1002/art.30613.
   Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–731. DOI:10.1016/S0140-6736(10)61354-2
   Google Scholar
• Stohl W, Schwarting A, Okada M, et al. A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE). Arthritis Rheumatol. 2015;67:(suppl 10):abstract number 3218. abstract.
   Google Scholar
• Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74:2006–2015. DOI:10.1136/annrheumdis-2013-205067.
   Google Scholar
• Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74:1667–1675. DOI:10.1136/annrheumdis-2013-205144
   Google Scholar
• Merrill JT, Van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled stu. Ann Rheum Dis. 2016;75(2):332.
   Google Scholar
• Rudnicka D, Oszmiana A, Finch DK, et al. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood. 2013;121:4694–4702. DOI:10.1182/blood-2013-02-482570
   Google Scholar
• Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005;17:282–289. DOI:10.1016/j.coi.2005.04.005.
   Google Scholar
• Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:2453–2459. DOI:10.1002/art.23678.
   Google Scholar
• Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3:e000118. DOI:10.1136/lupus-2015-000118.
   Google Scholar
• Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42:2288–2295. DOI:10.3899/jrheum.150470.
   Google Scholar
• Murphy G, Lisnevskaia L, Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet. 2013;382:809–818.
   Google Scholar
• Askanase AD, Yazdany J, Molta CT. Post-marketing experiences with belimumab in the treatment of SLE patients. Rheum Dis Clin North Am. 2014;40:507–17, viii. DOI:10.1016/j.rdc.2014.04.007.
   Google Scholar
• Yazdany J, Trupin L, Schmajuk G, et al. Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study. BMJ Qual Saf. 2014;23:659–666. DOI:10.1136/bmjqs-2013-002494.
   Google Scholar
• Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med. 2013;368:1528–1535. DOI:10.1056/NEJMct1207259.
   Google Scholar
• Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22:63–72. DOI:10.1177/0961203312465781.
   Google Scholar
• Dashiell A. Evaluation of the experience, satisfaction and outcomes of an autoinjector for self-administration of subcutaneous belimumab in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis 2016;75:1048-1049. DOI:10.1136/annrheumdis-2016-eular.4194.
   Google Scholar
• Sheikh SZ, Fox NL, Hammer AE, et al. Pharmacokinetics of switching from intravenous to subcutaneous belimumab for patients with systemic lupus erythematosus (SLE). Ann Rheum Dis 2016;75:297–298. DOI:10.1136/annrheumdis-2016-eular.4162.
   Google Scholar
• Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56:4142–4150. DOI:10.1002/art.23047.
   Google Scholar
• Morais SA, Vilas-Boas A, Isenberg DA. B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 2015;7:122–151. DOI:10.1177/1759720X15586782.
   Google Scholar
• Fairfax K, Mackay IR, Mackay F. BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus. IUBMB Life. 2012;64:595–602. DOI:10.1002/iub.1046.
   Google Scholar
• Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24:203–215. DOI:10.1016/j.cytogfr.2013.04.003.
   Google Scholar
• Yang M, Hase H, Legarda-Addison D, et al. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol. 2005;175:2814–2824. [cited 16 Nov2015]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16116167
   Google Scholar
• Stohl W, Merrill JT, Looney RJ, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist ‘peptibody’ blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015;17:215. DOI:10.1186/s13075-015-0741-z.
   Google Scholar
• Carbonatto M, Yu P, Bertolino M, et al. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci. 2008;105:200–210. DOI:10.1093/toxsci/kfn105.
   Google Scholar
• Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18:547–555. DOI:10.1177/0961203309102803.
   Google Scholar
• Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995–999. DOI:10.1038/35010115.
   Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14:R33. DOI:10.1186/ar3738.
   Google Scholar
• Isenberg DA. Meryl streep and the problems of clinical trials. Arthritis Res Ther. 2012;14:113. DOI:10.1186/ar3751.
   Google Scholar
• Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev. 2005;204:43–54. DOI:10.1111/j.0105-2896.2005.00219.x.
   Google Scholar
• Hsu H, Khare SD, Lee F, et al. A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. Clin Exp Rheumatol. [cited 2016 Jan 6]. 2012;30:197–201. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22325420
   Google Scholar
• Merrill JT, Strand V, Hislop C, et al. Exploratory results from the BLISS AND ILLUMINATE trials support the design of the CHABLIS-SC1 TRIAL, a randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of blisibimod administration in subjects with systemic L. Ann Rheum Dis. 2016;75(Suppl2):1047.
   Google Scholar
• Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2015;2015:207653. annrheumdis. DOI:10.1136/annrheumdis-2015-207653
   Google Scholar
• Edwards JCW, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581. DOI:10.1056/NEJMoa032534.
   Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806. DOI:10.1002/art.22025.
   Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390–1400. DOI:10.1002/art.21778.
   Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–233. DOI:10.1002/art.27233.
   Google Scholar
• Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009;18:767–776. DOI:10.1177/0961203309106174.
   Google Scholar
• Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72:1280–1286. DOI:10.1136/annrheumdis-2012-202844.
   Google Scholar
• Davies RJ, Sangle SR, Jordan NP, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013;22:574–582. DOI:10.1177/0961203313483376.
   Google Scholar
• Cobo-Ibáñez T, Loza-Santamaría E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44:175–185. DOI:10.1016/j.semarthrit.2014.04.002.
   Google Scholar
• Bang S-Y, Lee CK, Kang YM, et al. Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus. Autoimmune Dis. 2012;2012:565039. DOI:10.1155/2012/565039.
   Google Scholar
• Roccatello D, Sciascia S, Baldovino S, et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment—Clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14:1123–1130. DOI:10.1016/j.autrev.2015.07.017.
   Google Scholar
• Weidenbusch M, Römmele C, Schröttle A, et al. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28:106–111. DOI:10.1093/ndt/gfs285
   Google Scholar
• Roccatello D1, Sciascia S, Rossi D, et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transpl. 2011;26:3987–3992.
   Google Scholar
• Gagez A-L, Cartron G. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 2014;26:484–491. DOI:10.1097/CCO.0000000000000107.
   Google Scholar
• Reddy V, Klein C, Isenberg DA, et al. Obinutuzumab outperforms rituximab at inducing B-cell cytotoxicity in vitro through Fc-mediated effector mechanisms in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheumatol. 2015; 67 (suppl 10). [accessed 2016 Nov 10]. Available from: http://acrabstracts.org/abstract/obinutuzumab-outperforms-rituximab-at-inducing-b-cell-cytotoxicity-in-vitro-through-fc-mediated-effector-mechanisms-in-rheumatoid-arthritis-and-systemic-lupus-erythematosus/.
   Google Scholar
• Leone A, Sciascia S, Kamal A, et al. Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol. 2015;11:109–116. DOI:10.1586/1744666X.2015.994508.
   Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65:2368–2379. DOI:10.1002/art.38037.
   Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121–2131. DOI:10.1002/art.10461.
   Google Scholar
• Wallace DJ, Goldenberg DM. Epratuzumab for systemic lupus erythematosus. Lupus. 2013;22:400–405. DOI:10.1177/0961203312469692.
   Google Scholar
• Strand V, Petri M, Kalunian K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford). 2014;53:502–511. DOI:10.1093/rheumatology/ket378.
   Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73:183–190. DOI:10.1136/annrheumdis-2012-202760.
   Google Scholar
• Megan EB, Clowse G, Wallace DJ, et al. Efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus: results from two phase 3 randomized, placebo-controlled trials - ACR meeting abstracts. Arthritis Rheumatol. 2015;67((suppl):10.
   Google Scholar
• Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res. 2014;2014:419029. DOI:10.1155/2014/419029.
   Google Scholar
• Comte D, Karampetsou MP, Tsokos GC. T cells as a therapeutic target in SLE. Lupus. 2015;24:351–363. DOI:10.1177/0961203314556139.
   Google Scholar
• Brück W, Zamvil SS. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Clin Pharmacol. 2012;5:245–256. DOI:10.1586/ecp.12.12.
   Google Scholar
• Sthoeger ZM, Sharabi A, Molad Y, et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (edratide): immunomodulation of gene expression. J Autoimmun. 2009;33:77–82. DOI:10.1016/j.jaut.2009.03.009.
   Google Scholar
• Urowitz MB, Isenberg DA, Wallace DJ. Safety and efficacy of hCDR1 (edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Sci Med. 2015;2:e000104. DOI:10.1136/lupus-2015-000104.
   Google Scholar
• Spritz RA, Strunk K, Surowy CS, et al. The human U1-70K snRNP protein: cDNA cloning, chromosomal localization, expression, alternative splicing and RNA-binding. Nucleic Acids Res. 1987;15:10373–10391. [cited 2016 Jan 6]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=339950&tool=pmcentrez&rendertype=abstract
   Google Scholar
• Monneaux F, Muller S. Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun Rev. 2004;3:16–24. DOI:10.1016/S1568-9972(03)00061-2.
   Google Scholar
• Muller S, Monneaux F, Schall N, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 2008;58:3873–3883. DOI:10.1002/art.24027.
   Google Scholar
• Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14:748–755. DOI:10.1038/nm1763.
   Google Scholar
• Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74:1474–1478. DOI:10.1136/annrheumdis-2014-206016.
   Google Scholar
• Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. [cited 2016 Jan 6] 2004;13:339–343. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2014821&tool=pmcentrez&rendertype=abstract
   Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542–552. DOI:10.1002/art.27221.
   Google Scholar
• Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013;65:2661–2671. DOI:10.1002/art.38091.
   Google Scholar
• Rovin BH, Van Vollenhoven RF, Aranow C, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol (Hoboken, NJ). 2016;68:2174–2183. DOI:10.1002/art.39722.
   Google Scholar
• Crow MK, Hooks JJ, Moutsopoulos HM, et al. Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin North Am. 2010;36:173–86, x. DOI:10.1016/j.rdc.2009.12.008.
   Google Scholar
• Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70:1905–1913. DOI:10.1136/ard.2010.144485.
   Google Scholar
• Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65:1011–1021. DOI:10.1002/art.37824.
   Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. [ cited 2016 Mar]; DOI:10.1136/annrheumdis-2015-208562
   Google Scholar
• McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012;64:3666–3676. DOI:10.1002/art.34632.
   Google Scholar
• Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford). 2013;52:1313–1322. DOI:10.1093/rheumatology/ket129.
   Google Scholar
• Zagury D, Le Buanec H, Mathian A, et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A. 2009;106:5294–5299. DOI:10.1073/pnas.0900615106.
   Google Scholar
• Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum. 2013;65:447–456. DOI:10.1002/art.37785.
   Google Scholar
• Merrill JT, Furie R, Werth VP, et al. Anifrolumab reduces disease activity in multiple organ domains in moderate to severe systemic lupus erythematosus (SLE). Ann Rheum Dis. 2016;75(Suppl2):293 2016.
   Google Scholar
• Martin DA, Amoura Z, Romero-Diaz J, et al. THU0389 A multiple dose study of AMG 811 (Anti-IFN-Gamma) in subjects with systemic lupus erythematosus and active nephritis. Ann Rheum Dis. 2015;74:337.2-337. DOI:10.1136/annrheumdis-2015-eular.2916.
   Google Scholar
• Mosca M, Baldini C, Bombardieri S. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Expert Opin Pharmacother. 2007;8:873–879. DOI:10.1517/14656566.8.6.873.
   Google Scholar
• Furie RA, Cash JM, Cronin ME, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol. 2001;28:257–265.
   Google Scholar
• Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008;58:2470–2480. DOI:10.1002/art.23673.
   Google Scholar
• Horowitz DM, Furie RA. Abetimus sodium: a medication for the prevention of lupus nephritis flares. Expert Opin Pharmacother. 2009;10:1501–1507. DOI:10.1517/14656560902946419.
   Google Scholar
• Zhu L-J, Yang X, Yu X-Q. Anti-TNF-alpha therapies in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:465898. DOI:10.1155/2010/465898.
   Google Scholar
• Billiet T, Rutgeerts P, Ferrante M, et al. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014;14:75–101. DOI:10.1517/14712598.2014.858695.
   Google Scholar
• Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339–353. DOI:10.1592/phco.30.4.339.
   Google Scholar
• Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219:209–218. DOI:10.1159/000233234.
   Google Scholar
• Aringer M, Graninger WB, Steiner G, et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004;50:3161–3169. DOI:10.1002/art.20576.
   Google Scholar
• European Medicines Agency. Enbrel summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/000262/WC500027361.pdf.
   Google Scholar
• Etanercept for the Treatment of Lupus Nephritis - Full Text View. 2016. [accessed 2016 Oct 2]. Available from: https://clinicaltrials.gov
   Google Scholar
• Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus - Full Text View. 2016. [accessed 2016 Oct 2]. Available from: https://clinicaltrials.gov
   Google Scholar
• Changes M. Infliximab (remicade) anti-TNF. Interactions. 1998;50:1–25.
   Google Scholar
• TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL) - Full Text View. 2016. [accessed 2016 Oct 2]. Available from: https://clinicaltrials.gov
   Google Scholar
• Dall’Era M, Davis J. CTLA4Ig: a novel inhibitor of costimulation. Lupus. [cited 2016 Jan 6] 2004;13:372–376. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15230295
   Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:3077–3087. DOI:10.1002/art.27601.
   Google Scholar
• Hoi A, Littlejohn G. Is there still a role for abatacept in the treatment of lupus? Expert Opin Biol Ther. 2014;14:1345–1350. DOI:10.1517/14712598.2014.935329.
   Google Scholar
• Furie R, Nicholls K, Cheng -T-T, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol (Hoboken, NJ). 2014;66:379–389. DOI:10.1002/art.38260.
   Google Scholar
• Serrano-Benavente B, Bello N, Nieto-González JC, et al. CLINICAL EXPERIENCE FROM ABATACEPT USE IN SYSTEMIC LUPUS ERYTHEMATOSUS: EFFECTIVENESS AND SAFETY. Ann Rheum Dis. 2016;75(Suppl2):300.
   Google Scholar
• Rosen H, Gonzalez-Cabrera PJ, Sanna MG, et al. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem. 2009;78:743–768. DOI:10.1146/annurev.biochem.78.072407.103733.
   Google Scholar
• Blaho VA, Hla T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev. 2011;111:6299–6320. DOI:10.1021/cr200273u.
   Google Scholar
• Wenderfer SE, Stepkowski SM, Braun MC. Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int. 2008;74:1319–1326. DOI:10.1038/ki.2008.396.
   Google Scholar
• Ogawa R, Takahashi M, Hirose S-I, et al. A novel sphingosine-1-phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis. Biochem Biophys Res Commun. 2007;361:621–628. DOI:10.1016/j.bbrc.2007.07.061.
   Google Scholar
• Isenberg D, Gordon C, Merrill J, et al. New therapies in systemic lupus erythematosus - trials, troubles and tribulations…. working towards a solution. Lupus. 2008;17:967–970. DOI:10.1177/0961203308095139.
   Google Scholar
• Dall’Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol. 2006;18:476–480. DOI:10.1097/01.bor.0000240357.22680.63.
   Google Scholar
• Yuen SY, Pope JE. Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology (Oxford). 2008;47:1367–1372. DOI:10.1093/rheumatology/ken230.
   Google Scholar
• Isenberg DA, Merrill JT. Why, why, why de-lupus (does so badly in clinical trials). Expert Rev Clin Immunol. 2016;12:95–98. DOI:10.1586/1744666X.2016.1112270.
   Google Scholar